Jeremy G. Chadwick, Chief Operating Officer at Kymera Therapeutics, Inc. (KYMR), sold 300 shares at $90.00 ($27K) on 2026-04-22, disclosed to the SEC on 2026-04-24.
Scheduled sale ($27k) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| KYMR | SELL | 2026-04-01 | $1.9M | — | Filing → |
| KYMR | SELL | 2026-03-25 | $18.0M | — | Filing → |
| KYMR | SELL | 2026-03-11 | $4.3M | — | Filing → |